Alpha-Tocopheryloxyacetic acid(Alpha-Tocopheryloxyacetic acid) - 在研适应症：淋巴瘤，肉瘤，宫颈癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

α-TEA、ALPHA-TEA

靶点-

作用机制

细胞凋亡刺激剂、免疫刺激剂

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病+ [1]

在研适应症

淋巴瘤肉瘤宫颈癌

非在研适应症

激素难治性乳腺癌HER2阳性转移性乳腺癌

原研机构

Veana Therapeutics, Inc.

在研机构

Veana Therapeutics, Inc.

非在研机构

Veana Therapeutics LLC

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C31H52O4

InChIKeyLCFWOFKPFDWYLR-CEFNRUSXSA-N

CAS号261929-52-6

关联

3

项与 Alpha-Tocopheryloxyacetic acid 相关的临床试验

JPRN-UMIN000046705 / CompletedIIT

Study of inactivation of SARS-CoV-2 in saliva by ingestion of a candy containing tea-derived components in healthy adults - Study of inactivation of SARS-CoV-2 in saliva by candy containing tea-derived components

开始日期2022-01-25

申办/合作机构

Kyoto Prefectural University of Medicine

NCT04120246 / Suspended临床1期

A Phase I Dose Escalation Trial of Alpha-Tocopheryloxyacetic Acid (α-TEA) in Patients With Treatment Refractory HER2+ Metastatic Breast Cancer

This phase I trial studies the side effects and best dose of alpha-TEA when given together with trastuzumab and to see how well they work for the treatment of HER2+ breast cancer that does not respond to treatment (refractory) and has spread to other places in the body (metastatic). Anti-cancer treatment, such as alpha-TEA, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Alpha-TEA may also alter cancer growth by stimulating the body's immune response against the tumor. Trastuzumab is a form of "targeted therapy" because it works by attaching itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the body's immune system. Giving alpha-TEA and trastuzumab may work better for the treatment of HER2+ refractory and metastatic breast cancer compared to usual treatment.

开始日期2020-04-08

申办/合作机构

Veana Therapeutics LLC

[+1]

NCT02192346 / Completed临床1期IIT

Phase I Study of Alpha-tocopheryloxyacetic Acid (α-TEA) in Patients With Advanced Cancer

The goal of this study is to find the highest dose of α-TEA that can be given to patients safely, to identify potential side effects of α-TEA, and to measure the amount of α-TEA in patients' blood.
Additional goals of this study are to monitor the effect on tumors, to check for specific immune cells circulating in the blood, and to see if there are certain features of tumors that make it possible to predict the response to α-TEA.

开始日期2014-08-04

申办/合作机构

Providence Health & Services

100 项与 Alpha-Tocopheryloxyacetic acid 相关的临床结果

登录后查看更多信息

100 项与 Alpha-Tocopheryloxyacetic acid 相关的转化医学

登录后查看更多信息

100 项与 Alpha-Tocopheryloxyacetic acid 相关的专利（医药）

登录后查看更多信息

225

项与 Alpha-Tocopheryloxyacetic acid 相关的文献（医药）

2024-10-01·JOURNAL OF DERMATOLOGY

Skin colonization by Staphylococcus aureus in hemodialysis patients with pruritus and the effect of Staphylococcus aureus‐secreted α‐toxin on filaggrin expression

Article

作者: Wu, Cheng‐Ching ; Chang, Long‐Sen ; Chen, Ying‐Jung ; Tsai, Yen‐Yu

Abstract:

Staphylococcus aureus (S. aureus) commonly reside on human skin in residents in long‐term care facilities, yet its colonization and impact on the skin of hemodialysis (HD) patients have yet to be studied. The aim of the present study was to investigate the colonization of S. aureus on the skin of pruritic and non‐pruritic HD patients, and the influence of S. aureus and S. aureus‐secreted α‐toxin on skin barrier function‐related protein expression. In this study, a higher relative S. aureus count in pruritic HD patients compared to non‐pruritic HD patients and healthy subjects were revealed by real‐time polymerase chain reaction. S. aureus and α‐toxin decreased mRNA and protein expression levels of aryl hydrocarbon receptor (AHR), ovo‐like transcriptional repressor 1 (OVOL1), and filaggrin (FLG) in keratinocytes. In addition, anti‐alpha‐hemolysin (anti‐hla) was used as an α‐toxin neutralizer, and it successfully abrogated S. aureus‐induced AHR, OVOL1, and FLG mRNA and protein expression downregulation. Mechanistically, α‐toxin could decrease FLG activity by preventing the recruitment of AHR to the FLG promoter region. In conclusion, pruritic HD patients had higher S. aureus colonization, with S. aureus‐secreted α‐toxin suppressing FLG expression through the AHR‐FLG axis.

2024-08-01·FREE RADICAL BIOLOGY AND MEDICINE

Deciphering the enigma of the function of alpha-tocopherol as a vitamin

Article

作者: Traber, Maret G

α-Tocopherol (α-T) is a vitamin, but the reasons for the α-T requirement are controversial. Given that α-T deficiency was first identified in embryos, we studied to the premier model of vertebrate embryo development, the zebrafish embryo. We developed an α-T-deficient diet for zebrafish and used fish consuming this diet to produce α-T deficient (E-) embryos. We showed that α-T deficiency causes increased lipid peroxidation, leading to metabolic dysregulation that impacts both biochemical and morphological changes at very early stages in development. These changes occur at an early developmental window, which takes place prior to an analogous time to when a human knows she is pregnant. We found that α-T limits the chain reaction of lipid peroxidation and protects metabolic pathways and integrated gene expression networks that control embryonic development. Importantly, not only is α-T critical during early development, but the neurodevelopmental process is highly dependent on α-T trafficking by the α-T transfer protein (TTPa). Data from both gene expression and evaluation of the metabolome in E- embryos suggest that the activity of the mechanistic Target of Rapamycin (mTOR) signaling pathway is dysregulated-mTOR is a master regulatory mechanism, which controls both metabolism and neurodevelopment. Our findings suggest that TTPa is needed not only for regulation of plasma α-T in adults but is a key regulator during embryogenesis.

2024-05-01·Biological trace element research

Co-administration of L-Ascorbic Acid and α-Tocopherol Alleviates Arsenic-Induced Immunotoxicities in the Thymus and Spleen by Dwindling Oxidative Stress-Induced Inflammation

Article

作者: Pal, Priyankar ; Pal, Ranjana ; Mukhopadhyay, Prabir Kumar ; Maity, Jeet

Herein, we investigated whether L-ascorbic acid (L-AA) and α-tocopherol (α-T) co-administration has the potential to alleviate arsenic-induced immunotoxicities in the thymus, spleen, and circulating leukocytes. Forty-eight adult male Wistar rats were randomly divided into four groups before the treatment: group I (control); group II (sodium arsenite, 3 mg/kg/day/rat); group III (sodium arsenite + L-AA (200 mg/kg/day/rat) and α-T (400 mg/kg/day/rat)); group IV (L-AA and α-T). The result showed that sodium arsenite exposure (consecutive 30 days) caused weight reduction, structural alterations in the thymus and spleen, accompanied by a decrease in thymocyte and splenocyte count. Decreased superoxide dismutase and catalase activity, increased malondialdehyde and protein-carbonyl content, reduced Nrf2 and Bcl2 expression, and increased p-ERK, NF-kβ, Bax, and cleaved-caspase-3 expression were also observed in the thymus and spleen of arsenic-exposed rats. Enhanced plasma ACTH and corticosterone, ROS-induced apoptosis of lymphocytes were also observed. L-AA and α-T co-administration has the potential to abrogate the deleterious impact of arsenic on the thymus, spleen, and circulating lymphocytes. Whole transcriptome analysis of leukocytes revealed that arsenic treatment augmented the expression of Itga4, Itgam, and MMP9 genes, which might help in transient migration of the leukocytes through the endothelial cell layer. Co-administration with L-AA and α-T maintained Itga4, Itgam, and MMP9 gene expression within leukocytes at a lower level.

1

项与 Alpha-Tocopheryloxyacetic acid 相关的新闻（医药）

2024-09-27

·BioSpace

Astria Therapeutics to Present at Upcoming Global Angioedema Forum

BOSTON--(BUSINESS WIRE)-- Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that leading HAE experts will present two posters at the Global Angioedema Forum (GAF) in Copenhagen, Denmark on October 4-5, 2024. Dr. Aleena Banerji, M.D., Associate Professor of Medicine at Harvard Medical School and Clinical Director of the Allergy and Immunology Unit at Massachusetts General Hospital, will present information on ALPHA-SOLAR, a long-term open-label trial of navenibart (STAR-0215) in people living with HAE, in an encore presentation of a poster titled “Rationale and Design of the ALPHA-SOLAR Clinical Trial of STAR-0215.” The poster session will take place on Friday, October 4 at 6:00pm CEST. Dr. William Lumry, M.D., Clinical Professor of Internal Medicine at the University of Texas Health Science Center at Dallas, will present results from the Phase 1b/2 trial of navenibart (STAR-0215) in an encore presentation of a poster titled “ALPHA-STAR, a Phase 1b/2 Clinical Trial of Single and Multiple Doses of STAR-0215 in Patients with Hereditary Angioedema: Initial Safety and Efficacy Outcomes.” The presentation will take place during a session titled “Emerging Treatment Options” on Saturday, October 5 at 9:30am CEST. About Astria Therapeutics: Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, , or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn. Contacts Astria Contact: Investor Relations and Media: Elizabeth Higgins investors@astriatx.com

临床研究

100 项与 Alpha-Tocopheryloxyacetic acid 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
激素难治性乳腺癌	临床1期	美国	Veana Therapeutics LLC	2020-04-08
HER2阳性转移性乳腺癌	临床1期	美国	Veana Therapeutics LLC	2020-04-08
淋巴瘤	临床1期	-	Veana Therapeutics, Inc.	-
肉瘤	临床1期	-	Veana Therapeutics, Inc.	-
宫颈癌	临床1期	-	Veana Therapeutics, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02192346 (P8, SITC2016)	临床1期	晚期癌症	12	Alpha-tocopheryloxyacetic acid (Î±-TEA) 2.4 mg/kg	顧廠淵糧壓網範鬱積壓(窪衊構獵窪繭選網膚衊) = 6 developed atrial fibrillation (AF) after starting Î±-TEA 積夢醖鑰糧糧簾餘襯獵 (艱鑰簾餘艱顧鹹築窪憲 ) 更多	积极	2016-12-08
NCT02192346 (P8, SITC2016)	临床1期	晚期癌症	12	Alpha-tocopheryloxyacetic acid (Î±-TEA) 4.8 mg/kg		积极	2016-12-08
NCT02192346 (SITC2015)	临床1期	晚期癌症 CD8 effector memory \| CD38 \| HLA-DR	-	Alpha-tocopheryloxyacetic acid (α-TEA) 4.8mg/kg	觸憲餘鹹窪襯壓觸鹽糧(窪鹽選選簾鑰糧顧觸鹹) = 醖糧齋網觸窪糧鏇衊壓糧鏇築獵觸淵蓋淵糧鏇 (壓糧積鏇窪醖築憲糧鹹 )	积极	2015-11-04